霍奇金淋巴瘤 (HL) 是一种罕见的 B 细胞淋巴恶性肿瘤，每年影响 8570 名新患者，约占美国所有淋巴瘤的 10%。HL 由两种不同的疾病实体组成：经典 HL 和结节性淋巴细胞为主的 HL（也称为结节性淋巴细胞为主的 B 细胞淋巴瘤）。结节性硬化症、混合细胞性、淋巴细胞耗竭型和淋巴细胞富集型 HL 是经典 HL 的亚型。准确评估 HL 患者的疾病阶段对于选择适当的治疗至关重要。预后模型可识别复发风险低或高的患者，以及通过正电子发射断层扫描 (PET) 扫描确定的治疗反应，用于优化治疗。HL 患者的初始治疗基于疾病的组织学、解剖分期和不良预后特征的存在。早期疾病患者通常采用联合治疗策略，即缩短疗程的联合化疗，然后进行受累野放射治疗，而晚期疾病患者则接受较长疗程的化疗，通常不进行放射治疗。然而，包括 brentuximab vedotin 和抗 PD-1 抗体在内的较新药物现已标准纳入一线治疗中。高剂量化疗 (HDCT) 随后进行自体干细胞移植 (ASCT) 是大多数术后复发患者的标准治疗方法初始治疗。对于 HDCT 与 ASCT 失败的患者，应考虑 brentuximab vedotin、PD-1 阻断、非清髓性同种异体移植或参与临床试验。© 2024 Wiley periodicals LLC。

Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8570 new patients annually and representing ~10% of all lymphomas in the United States.HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL (also called nodular lymphocyte predominant B-cell lymphoma). Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL.An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography (PET) scan, are used to optimize therapy.Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early-stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, whereas those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. However, newer agents including brentuximab vedotin and anti-PD-1 antibodies are now standardly incorporated into frontline therapy.High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant or participation in a clinical trial should be considered.© 2024 Wiley Periodicals LLC.